Endpoints News

#EHA25: Gilead, Arcellx continue to tout safety of multiple myeloma cell therapy anito-cel

over 1 year ago

Gilead and Arcellx reported that their multiple myeloma CAR-T therapy continued to...

Lilly posts encouraging early-stage weight loss data on amylin candidate

over 1 year ago

Eli Lilly’s under-the-radar amylin analog allowed obese patients in a Phase 1...

Supernus to acquire Sage Therapeutics for about $561M

over 1 year ago

Sage Therapeutics has finally found a buyer It will be acquired by...

Endpoints 11 nominations: Help us find 2025's best biotech startups

over 1 year ago

NextCure inks ADC deal with Simcere Zaiming

over 1 year ago

NextCure will be paying up to $745 million for the ex-Greater China...

Incyte’s promising thrombocythemia drug; Crescent Biopharma raises $200M in PIPE

over 1 year ago

Plus, news about D&D Pharmatech and Jasper Therapeutics Incyte’s thrombocythemia win: The...

Roche moves ahead with Phase 3 Parkinson’s study despite mixed trial results

over 1 year ago

Roche and Prothena said they're planning to proceed with a Phase 3...

AbbVie's Venclexta fails Phase 3 study in other bone marrow cancers

over 1 year ago

AbbVie said Venclexta did not improve survival in patients with myelodysplastic syndromes...

FDA chief Makary predicts a universal flu vaccine in next five years

over 1 year ago

WASHINGTON — When it comes to pharma innovation over the next several...

Eli Lilly makes all Zepbound doses available in single-dose vials

over 1 year ago

Eli Lilly said it will make the two highest doses of its...

Purdue opioid settlement gets backing from 55 attorneys general

over 1 year ago

Nearly every state in the US has agreed to a $7.4 billion...

Fired vaccine advisors defend ACIP's work in joint editorial

over 1 year ago

All 17 ousted members of a key CDC vaccine panel say their...